Chest
Original ResearchSarcoidosisResults of 188 Whole-Body Fluorodeoxyglucose Positron Emission Tomography Scans in 137 Patients With Sarcoidosis
Section snippets
Materials and Methods
All patients attended the sarcoidosis service at Mount Sinai Medical Center (New York, NY). A total of 88 patients underwent whole-body scans as part of a study of perfusion (82Rb) and metabolic FDG PET scan imaging for the diagnosis and treatment of cardiac sarcoidosis. In addition, 49 patients underwent only whole-body FDG PET scans for one of the following indications: (1) seeking a diagnostic biopsy site not identified by standard techniques; and (2) identifying reversible granulomatous
Results
There were 72 men and 65 women in the study; 68 were white, 63 were African American, and 6 were other. The mean age was 50.4 years (age range, 19 to 81 years).
A total of 139 of the 188 FDG PET scans revealed hypermetabolism in the 137 patients. Table 1shows the results of the 139 extracardiac positive FDG PET scan findings in 137 patients. Forty-nine scans exhibited no extracardiac uptake of FDG. Mediastinal and extrathoracic lymph nodes and lungs were the most common sites of extracardiac PET
Discussion
In the vast majority of patients with sarcoidosis, the diagnosis is available by biopsy of a wide variety of organs. Twenty-six diagnostic biopsy sites were reported in A Case Controlled Etiologic Study of Sarcoidosis.9 Rarely, the clinical presentation suggests the diagnosis of sarcoidosis, but no readily available biopsy site is identified or only a single organ system is involved (eg, the patient who presents with anterior uveitis, normal chest radiograph findings, and no other imaging or
References (14)
- et al.
Diagnostic usefulness of fluorine-18-α-methyltyrosine positron emission tomography in combination with18F-fluorodeoxyglucose in sarcoidosis patients
Chest
(2007) - et al.
Statement on sarcoidosis: joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999
Am J Respir Crit Care Med
(1999) F-18 FDG PET imaging of disseminated sarcoidosis
Clin Nucl Med
(2007)- et al.
Gallium-67 imaging in patients with dilated cardiomyopathy and biopsy-proven myocarditis
Circulation
(1984) - et al.
Value of FDG positron emission tomography in monitoring the effects of therapy in progressive pulmonary sarcoidosis
Clin Nucl Med
(2007) - et al.
Imaging guidelines for nuclear cardiology procedures: PET myocardial perfusion and glucose metabolism imaging
J Nucl Cardiol
(2006) - et al.
Normal values and evaluation of forced end-expiratory flow
Am Rev Respir Dis
(1975)
Cited by (274)
Uncommon diagnosis of multinodular goiter – isolated extrapulmonary manifestation of sarcoidosis in thyroid gland (scientific case reports)
2024, Pathology Research and PracticeDiagnosis of Pulmonary Sarcoidosis
2024, Clinics in Chest MedicineDiagnostic yield of whole-body <sup>18</sup>F-FDG PET/CT in patients with suspected cardiac sarcoidosis
2023, Journal of Nuclear CardiologyThe Management of Sarcoidosis in the 2020s by the Primary Care Physician
2023, American Journal of MedicineFDG PET/CT Imaging of Sarcoidosis
2023, Seminars in Nuclear MedicineCitation Excerpt :Combining anatomic evaluation by CT and metabolic assessment by FDG, FDG-PET/CT identifies active inflammation in lymph nodes and parenchymal lesions with a high sensitivity, ranging between 94% and 100% and a very good inter-observer agreement.44,45 Studies comparing FDG-PET to chest X-rays showed that PET identifies more lesions, notably in extra-thoracic sites and that some anatomic lesions on chest x-rays are non FDG avid46-48 more frequently in stages I and IV. Moreover, FDG-PET/CT enables identification of sarcoid lesions not detected on chest CT,49 predominantly lymphadenopathy of normal shape on CT and extra-thoracic disease (Fig. 1).
All authors listed have no actual or potential conflicts of interest.